HIGHTIDE-B (02511): Gao Liping has been appointed as the joint company secretary.

HIGHTIDE-B (02511) has announced that due to the need to allocate more time to other work arrangements, Yu Li has submitted...

Zhitong FinanceDec 19 22:34

HighTide Therapeutics to Cooperate on Chronic Diseases, Longevity, Anti-Aging With SSY Group

MT NewswiresDec 19 18:23

SSY GROUP (02005.HK) has signed a framework agreement with Junshentai Pharmaceutical for joint research and development.

On December 19, Gelonghui reported that SSY GROUP (02005.HK) announced that its wholly-owned subsidiary, Shijiazhuang Four Pharmaceuticals Co., Ltd., has entered into a strategic cooperation framework agreement with HIGHTIDE-B (02511.HK) and its wholly-owned subsidiary ("Partner"). The agreement aims to combine the group's extensive experience in active screening, formulation development, achievement transformation, quality, and cost control, along with HIGHTIDE-B's unique advantages in the field of natural product multi-system collaborative innovation, to tackle industry challenges and provide breakthrough solutions for Global metabolic diseases and longevity anti-aging.

Gelonghui FinanceDec 19 16:35

HIGHTIDE-B (02511.HK) has appointed DaHua Ma Shi Yun as its auditor.

On December 11, Gelonghui announced that HIGHTIDE-B (02511.HK) has received notice of resignation from Ernst & Young as the company's auditor, effective from December 11, 2024, due to the inability to reach an agreement on the proposed audit fees for the year ending December 31, 2024. The Board of Directors further announced that, following recommendations from the audit committee, it has resolved to appoint Deloitte as the new auditor of the company, effective from December 11, 2024, to fill the interim vacancy left by Ernst & Young's resignation, and it is expected that Deloitte will serve until the company is...

Gelonghui FinanceDec 11 19:11

HIGHTIDE-B: 2024 Interim Report

HKEXSep 27 16:30 · Announcements

HK stocks anomaly | Jun Sheng Tai Medicine-B (02511) plunged 41%, removed from the Hong Kong Stock Connect, with a total market value evaporating over 6 billion Hong Kong dollars.

Junshengtai Medicine-B (02511) plummeted by 41%, hitting a new low of 0.72 Hong Kong dollars. The current market cap is less than 0.5 billion Hong Kong dollars, evaporating over 6 billion Hong Kong dollars from its peak value.

Zhitong FinanceSep 10 10:12